Terms: = Colorectal cancer AND RBM15, Q96T37, 64783, ENSG00000162775, OTT, OTT1
19 results:
1. Regulatory mechanism of RNA binding motif protein 15-mediated N
Chen J
Environ Toxicol; 2023 Nov; 38(11):2545-2559. PubMed ID: 37471637
[TBL] [Abstract] [Full Text] [Related]
2. Construction and validation of stemness-related lncRNA pair signature for predicting prognosis in colorectal cancer.
Thandar M; Zhu Y; Zhang X; Chen Z; Zhao Y; Huang S; Chi P
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11815-11828. PubMed ID: 37410143
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer.
Jiang T; Xing L; Zhao L; Ye Z; Yu D; Lin S
BMC Med Genomics; 2023 May; 16(1):105. PubMed ID: 37194014
[TBL] [Abstract] [Full Text] [Related]
4. Intensity-modulated radiotherapy and cisplatin-based chemotherapy for anal cancer: long-term outcomes at a single institution.
Gerardi MA; Zerella MA; Bergamaschi L; Ferrari A; Arculeo S; Bagnardi V; Frassoni S; Petz W; Fodor C; Emiro F; Cattani F; Leonardi MC; Zampino MG; Jereczek-Fossa BA
Int J Colorectal Dis; 2023 May; 38(1):123. PubMed ID: 37162567
[TBL] [Abstract] [Full Text] [Related]
5. Knockdown rbm15 Inhibits colorectal cancer Cell Proliferation and Metastasis Via N6-Methyladenosine (m6A) Modification of MyD88 mRNA.
Zhang Z; Mei Y; Hou M
Cancer Biother Radiopharm; 2022 Dec; 37(10):976-986. PubMed ID: 34842457
[TBL] [Abstract] [Full Text] [Related]
6. Gene Alterations of N6-Methyladenosine (m
Zhang Q; Cai Y; Kurbatov V; Khan SA; Lu L; Zhang Y; Johnson CH
Biomed Res Int; 2020; 2020():8826456. PubMed ID: 33415160
[TBL] [Abstract] [Full Text] [Related]
7. The optimal timing for the interval to surgery after short course preoperative radiotherapy (5 ×5 Gy) in rectal cancer - are we too eager for surgery?
Glynne-Jones R; Hall M; Nagtegaal ID
Cancer Treat Rev; 2020 Nov; 90():102104. PubMed ID: 33002819
[TBL] [Abstract] [Full Text] [Related]
8. The Prognostic Value of m6A RNA Methylation Regulators in Colon Adenocarcinoma.
Liu T; Li C; Jin L; Li C; Wang L
Med Sci Monit; 2019 Dec; 25():9435-9445. PubMed ID: 31823961
[TBL] [Abstract] [Full Text] [Related]
9. Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal cancer (PARADAC).
Rivin Del Campo E; Matzinger O; Haustermans K; Peiffert D; Glynne-Jones R; Winter KA; Konski AA; Ajani JA; Bosset JF; Hannoun-Levi JM; Puyraveau M; Chakravarthy AB; Meadows H; Northover J; Collette L; Christiaens M; Maingon P
Eur J Cancer; 2019 Nov; 121():130-143. PubMed ID: 31574418
[TBL] [Abstract] [Full Text] [Related]
10. Postoperative complications in relation to overall treatment time in patients with rectal cancer receiving neoadjuvant radiotherapy.
Erlandsson J; Pettersson D; Glimelius B; Holm T; Martling A
Br J Surg; 2019 Aug; 106(9):1248-1256. PubMed ID: 31197822
[TBL] [Abstract] [Full Text] [Related]
11. Anal carcinoma: surgery does not influence prognosis when performed prior to concurrent radiochemotherapy.
Badakhshi H; Budach V; Wust P; Graf R
Anticancer Res; 2013 Sep; 33(9):4111-5. PubMed ID: 24023357
[TBL] [Abstract] [Full Text] [Related]
12. "Mind the gap"--the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal cancer Trial (ACT I).
Glynne-Jones R; Sebag-Montefiore D; Adams R; McDonald A; Gollins S; James R; Northover JM; Meadows HM; Jitlal M;
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1488-94. PubMed ID: 20934265
[TBL] [Abstract] [Full Text] [Related]
13. High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study).
Hannoun-Levi JM; Ortholan C; Resbeut M; Teissier E; Ronchin P; Cowen D; Zaccariotto A; Bénézery K; François E; Salem N; Ellis S; Azria D; Gerard JP
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):712-20. PubMed ID: 20619552
[TBL] [Abstract] [Full Text] [Related]
14. Bromodeoxyuridine labeling index as an indicator of early tumor response to preoperative radiotherapy in patients with rectal cancer.
Gasinska A; Skolyszewski J; Popiela T; Richter P; Darasz Z; Nowak K; Niemiec J; Biesaga B; Adamczyk A; Bucki K; Malecki K; Reinfuss M; Kowalska T
J Gastrointest Surg; 2007 Apr; 11(4):520-8. PubMed ID: 17436139
[TBL] [Abstract] [Full Text] [Related]
15. Preoperative hyper-fractionated accelerated radiotherapy (HART) in locally advanced rectal cancer (LARC) immediately followed by surgery. A prospective phase II trial.
Coucke PA; Notter M; Stamm B; Matter M; Fasolini F; Schlumpf R; Matzinger O; Bouzourene H;
Radiother Oncol; 2006 Apr; 79(1):52-8. PubMed ID: 16564590
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma.
Allal AS; Waelchli L; Bründler MA
Clin Cancer Res; 2003 Dec; 9(17):6489-96. PubMed ID: 14695153
[TBL] [Abstract] [Full Text] [Related]
17. Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy.
Graf R; Wust P; Hildebrandt B; Gögler H; Ullrich R; Herrmann R; Riess H; Felix R
Oncology; 2003; 65(1):14-22. PubMed ID: 12837978
[TBL] [Abstract] [Full Text] [Related]
18. Retrospective study of acute toxicity following short-course preoperative radiotherapy.
Hartley A; Giridharan S; Gray L; Billingham L; Ismail T; Geh JI
Br J Surg; 2002 Jul; 89(7):889-95. PubMed ID: 12081739
[TBL] [Abstract] [Full Text] [Related]
19. The impact of treatment factors on local control in T2-T3 anal carcinomas treated by radiotherapy with or without chemotherapy.
Allal AS; Mermillod B; Roth AD; Marti MC; Kurtz JM
Cancer; 1997 Jun; 79(12):2329-35. PubMed ID: 9191520
[TBL] [Abstract] [Full Text] [Related]